Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia

Frans Debruyne, Jack Barkin, Peter Van Erps, Mario Reis, Teuvo L J Tammela, Claus Roehrborn

Research output: Contribution to journalArticle

182 Citations (Scopus)

Abstract

Dutasteride, a dual inhibitor of Type 1 and Type 2 5α-reductase, has been shown to improve disease measures in patients with symptomatic benign prostatic hyperplasia (BPH) in three randomised, placebo-controlled, large-scale, 2-year Phase III clinical studies. This paper reports the pooled results of a 2-year open-label extension of the three randomised studies assessing the long-term efficacy and safety of dutasteride.Patients randomised to dutasteride or placebo in the double-blind portion of the Phase III studies were eligible for a 2-year open-label extension, where all patients received dutasteride 0.5 mg daily (dutasteride/dutasteride [D/D] group and placebo/dutasteride [P/D group]).Significant improvements in AUA-SI score and Q max were observed from Month 24 to 48 in both study groups. At Month 48, patients in the D/D group had significantly greater improvements in AUA-SI score and Q max, and significantly greater reductions in prostate volume, than those in the P/D group. Acute urinary retention and BPH-related surgery occurred in a small percentage of patients during the open-label phase. No new safety issues were noted with long-term therapy. Onset of new drug-related adverse events were reported most frequently at the start of therapy and declined over time in patients receiving dutasteride.Long-term treatment with dutasteride results in continuing improvements in urinary symptoms and flow rate, and further reductions in TPV, in men with symptomatic BPH. The reduction in risk of AUR and BPH-related surgery, seen in the double-blind phase, was durable over 4-year treatment. Dutasteride was also well tolerated in long-term use.

Original languageEnglish (US)
Pages (from-to)488-495
Number of pages8
JournalEuropean Urology
Volume46
Issue number4
DOIs
StatePublished - Oct 2004

Fingerprint

Prostatic Hyperplasia
Oxidoreductases
Safety
Therapeutics
Placebos
Dutasteride
Urinary Retention
Risk Reduction Behavior
Drug-Related Side Effects and Adverse Reactions
Prostate

Keywords

  • 5α-reductase inhibitor
  • BPH
  • Dutasteride
  • Long term
  • Lower urinary tract symptoms

ASJC Scopus subject areas

  • Urology

Cite this

Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. / Debruyne, Frans; Barkin, Jack; Erps, Peter Van; Reis, Mario; Tammela, Teuvo L J; Roehrborn, Claus.

In: European Urology, Vol. 46, No. 4, 10.2004, p. 488-495.

Research output: Contribution to journalArticle

Debruyne, Frans ; Barkin, Jack ; Erps, Peter Van ; Reis, Mario ; Tammela, Teuvo L J ; Roehrborn, Claus. / Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. In: European Urology. 2004 ; Vol. 46, No. 4. pp. 488-495.
@article{f278e3dd215f408f98e9bd1a98331802,
title = "Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia",
abstract = "Dutasteride, a dual inhibitor of Type 1 and Type 2 5α-reductase, has been shown to improve disease measures in patients with symptomatic benign prostatic hyperplasia (BPH) in three randomised, placebo-controlled, large-scale, 2-year Phase III clinical studies. This paper reports the pooled results of a 2-year open-label extension of the three randomised studies assessing the long-term efficacy and safety of dutasteride.Patients randomised to dutasteride or placebo in the double-blind portion of the Phase III studies were eligible for a 2-year open-label extension, where all patients received dutasteride 0.5 mg daily (dutasteride/dutasteride [D/D] group and placebo/dutasteride [P/D group]).Significant improvements in AUA-SI score and Q max were observed from Month 24 to 48 in both study groups. At Month 48, patients in the D/D group had significantly greater improvements in AUA-SI score and Q max, and significantly greater reductions in prostate volume, than those in the P/D group. Acute urinary retention and BPH-related surgery occurred in a small percentage of patients during the open-label phase. No new safety issues were noted with long-term therapy. Onset of new drug-related adverse events were reported most frequently at the start of therapy and declined over time in patients receiving dutasteride.Long-term treatment with dutasteride results in continuing improvements in urinary symptoms and flow rate, and further reductions in TPV, in men with symptomatic BPH. The reduction in risk of AUR and BPH-related surgery, seen in the double-blind phase, was durable over 4-year treatment. Dutasteride was also well tolerated in long-term use.",
keywords = "5α-reductase inhibitor, BPH, Dutasteride, Long term, Lower urinary tract symptoms",
author = "Frans Debruyne and Jack Barkin and Erps, {Peter Van} and Mario Reis and Tammela, {Teuvo L J} and Claus Roehrborn",
year = "2004",
month = "10",
doi = "10.1016/j.eururo.2004.05.008",
language = "English (US)",
volume = "46",
pages = "488--495",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "4",

}

TY - JOUR

T1 - Efficacy and safety of long-term treatment with the dual 5α-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia

AU - Debruyne, Frans

AU - Barkin, Jack

AU - Erps, Peter Van

AU - Reis, Mario

AU - Tammela, Teuvo L J

AU - Roehrborn, Claus

PY - 2004/10

Y1 - 2004/10

N2 - Dutasteride, a dual inhibitor of Type 1 and Type 2 5α-reductase, has been shown to improve disease measures in patients with symptomatic benign prostatic hyperplasia (BPH) in three randomised, placebo-controlled, large-scale, 2-year Phase III clinical studies. This paper reports the pooled results of a 2-year open-label extension of the three randomised studies assessing the long-term efficacy and safety of dutasteride.Patients randomised to dutasteride or placebo in the double-blind portion of the Phase III studies were eligible for a 2-year open-label extension, where all patients received dutasteride 0.5 mg daily (dutasteride/dutasteride [D/D] group and placebo/dutasteride [P/D group]).Significant improvements in AUA-SI score and Q max were observed from Month 24 to 48 in both study groups. At Month 48, patients in the D/D group had significantly greater improvements in AUA-SI score and Q max, and significantly greater reductions in prostate volume, than those in the P/D group. Acute urinary retention and BPH-related surgery occurred in a small percentage of patients during the open-label phase. No new safety issues were noted with long-term therapy. Onset of new drug-related adverse events were reported most frequently at the start of therapy and declined over time in patients receiving dutasteride.Long-term treatment with dutasteride results in continuing improvements in urinary symptoms and flow rate, and further reductions in TPV, in men with symptomatic BPH. The reduction in risk of AUR and BPH-related surgery, seen in the double-blind phase, was durable over 4-year treatment. Dutasteride was also well tolerated in long-term use.

AB - Dutasteride, a dual inhibitor of Type 1 and Type 2 5α-reductase, has been shown to improve disease measures in patients with symptomatic benign prostatic hyperplasia (BPH) in three randomised, placebo-controlled, large-scale, 2-year Phase III clinical studies. This paper reports the pooled results of a 2-year open-label extension of the three randomised studies assessing the long-term efficacy and safety of dutasteride.Patients randomised to dutasteride or placebo in the double-blind portion of the Phase III studies were eligible for a 2-year open-label extension, where all patients received dutasteride 0.5 mg daily (dutasteride/dutasteride [D/D] group and placebo/dutasteride [P/D group]).Significant improvements in AUA-SI score and Q max were observed from Month 24 to 48 in both study groups. At Month 48, patients in the D/D group had significantly greater improvements in AUA-SI score and Q max, and significantly greater reductions in prostate volume, than those in the P/D group. Acute urinary retention and BPH-related surgery occurred in a small percentage of patients during the open-label phase. No new safety issues were noted with long-term therapy. Onset of new drug-related adverse events were reported most frequently at the start of therapy and declined over time in patients receiving dutasteride.Long-term treatment with dutasteride results in continuing improvements in urinary symptoms and flow rate, and further reductions in TPV, in men with symptomatic BPH. The reduction in risk of AUR and BPH-related surgery, seen in the double-blind phase, was durable over 4-year treatment. Dutasteride was also well tolerated in long-term use.

KW - 5α-reductase inhibitor

KW - BPH

KW - Dutasteride

KW - Long term

KW - Lower urinary tract symptoms

UR - http://www.scopus.com/inward/record.url?scp=4444336295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4444336295&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2004.05.008

DO - 10.1016/j.eururo.2004.05.008

M3 - Article

C2 - 15363566

AN - SCOPUS:4444336295

VL - 46

SP - 488

EP - 495

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 4

ER -